SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Japanese Patent Grant for Sareum's Kinase Inhibitors
Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Company has been notified by the Japan Patent Office that a patent has been granted for one of Sareum's key drug discovery inventions.
This patent*, which relates to compounds that inhibit or modulate the activity of kinase enzymes, forms the basis of Sareum's SKIL® drug discovery platform. The granting of this patent means that Sareum has approved patent protection in the Japan for its SKIL platform and many of its drug discovery programmes. The Company expects to receive similar protection in Europe and other major markets in due course.
SKIL (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.
* Patent No. 5555620,
Sareum's CSO, Dr John Reader, commented: "The granting of this patent in Japan strengthens our patent portfolio, and enhances our negotiating position with potential licensing partners".
Enquiries: Sareum Holdings plc |
|
Tim Mitchell |
01223 497 700 |
Sanlam Securities UK Limited (Nomad) |
Simon Clements / James Thomas |
020 7628 2200 |
Hybridan LLP (Broker) |
|
Claire Noyce / William Lynne |
0203 713 4581/ 4582 |
The Communications Portfolio (Media enquiries) |
|
Ariane Comstive
[email protected] |
020 7536 2028 |
Notes for editors:
About Sareum Holdings plc
Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.
SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk
- Ends -
